Summary Millendo Therapeutics Inc (Millendo Therapeutics), formerly Atterocor Inc develops treatments for endocrine diseases including vasomotor. The company provides development of innovative treatments for orphan endocrine disorders such as adrenocortical carcinoma caused by hormone abnormalities. Its pipeline products include MLE4901 and ATR-101. Millendo Therapeutics' MLE4901 product is used for the treatment of polycystic ovary syndrome. The company's MLE4901 is a neurokinin 3 receptor antagonist that helps decrease gonadotropin releasing hormone hyperpulsatility and luteinizing hormone pulse frequency. Its ATR-101, is used to treat ACC, congenital adrenal hyperplasia and endogenous cushing’s syndrome. The company provides treatments for endocrine diseases caused by hormone dysregulation of medications exist. Millendo Therapeutics is headquartered in Ann Arbor, Michigan, the US. Millendo Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report... Research Beam Model: Research Beam Product ID: 1995477 250 USD New
Millendo Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

Millendo Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Company Profiles
  • Published On : August   2017
  • Pages : 31
  • Publisher : GlobalData
 
 
 
Summary

Millendo Therapeutics Inc (Millendo Therapeutics), formerly Atterocor Inc develops treatments for endocrine diseases including vasomotor. The company provides development of innovative treatments for orphan endocrine disorders such as adrenocortical carcinoma caused by hormone abnormalities. Its pipeline products include MLE4901 and ATR-101. Millendo Therapeutics' MLE4901 product is used for the treatment of polycystic ovary syndrome. The company's MLE4901 is a neurokinin 3 receptor antagonist that helps decrease gonadotropin releasing hormone hyperpulsatility and luteinizing hormone pulse frequency. Its ATR-101, is used to treat ACC, congenital adrenal hyperplasia and endogenous cushing’s syndrome. The company provides treatments for endocrine diseases caused by hormone dysregulation of medications exist. Millendo Therapeutics is headquartered in Ann Arbor, Michigan, the US.

Millendo Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Millendo Therapeutics Raises USD62 Million in Series B Venture Financing 10
Millendo Therapeutics Secures USD16 Million in Series A Venture Funding 12
Atterocor Raises US$16 Million In Series A Financing 13
Atterocor Raises US$0.3 Million In Venture Financing 14
Licensing Agreements 15
Millendo Therapeutics Enters into Licensing Agreement with AstraZeneca for MLE4901 15
Millendo Therapeutics Inc - Key Competitors 16
Millendo Therapeutics Inc - Key Employees 17
Millendo Therapeutics Inc - Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Corporate Communications 19
Apr 11, 2017: Millendo Therapeutics Appoints Mary Lynne Hedley, Ph.D. and Carole Nuechterlein, J.D. to Board of Directors 19
Nov 17, 2016: Millendo Therapeutics appoints new CFO 20
Jun 23, 2016: Millendo Therapeutics Appoints New Independent Board Member and Names Chairperson of the Board 21
Clinical Trials 22
May 15, 2017: Millendo Therapeutics Announces MLE4901 Data Presentations at European Congress of Endocrinology and Congress of the European Menopause and Andropause Society 22
Apr 03, 2017: Millendo Therapeutics Announces Publication of Positive Phase 2 Data for MLE4901 for the Treatment of Vasomotor Symptoms 23
Mar 23, 2017: Millendo Therapeutics Announces Data Presentations for MLE4901 at ENDO 2017 and Kisspeptin 2017 24
Nov 03, 2016: Millendo Therapeutics Announces Data Presentations at Androgen Excess and Polycystic Ovary Syndrome Society Annual Meeting 26
Nov 02, 2016: Millendo Therapeutics to present data on MLE-4901 program at Society for Endocrinology British Endocrine Societies Conference 27
Aug 16, 2016: Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of MLE4901 in Patients with Polycystic Ovary Syndrome 28
Jul 27, 2016: Millendo Therapeutics Announces Publication of Positive Phase 2a Data for MLE4901 for the Treatment of Polycystic Ovary Syndrome 29
Mar 18, 2016: Millendo Therapeutics Announces Publication of Preclinical Data for ATR-101 and Data Presentations at ENDO 2016 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Millendo Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Millendo Therapeutics Raises USD62 Million in Series B Venture Financing 10
Millendo Therapeutics Secures USD16 Million in Series A Venture Funding 12
Atterocor Raises US$16 Million In Series A Financing 13
Atterocor Raises US$0.3 Million In Venture Financing 14
Millendo Therapeutics Enters into Licensing Agreement with AstraZeneca for MLE4901 15
Millendo Therapeutics Inc, Key Competitors 16
Millendo Therapeutics Inc, Key Employees 17
List of Figures
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter